Apr
20
Friday

VRTX 158.15 -1.40 (-0.88%)

Sections on this page: Stock Price | Stock Charts | Company Profile | Earnings


Would you like to receive important updates about Vertex Pharmaceuticals Inc like earnings dates and more?

Add (VRTX) to Portfolio

VRTX Stock Price Today $158.15

 The recent VRTX stock price today is $158.15 -1.40 (-0.88%) for Fri, Apr 20, 2018.

Year To Date

The Year To Date (YTD) return is +3.43%.

52 Week Low

May 2017
05
Friday

The 52 Week Low stock price is 113.66 set on Fri, May 5, 2017 which is 351 days ago.

The current price per share is 39.14% above the 52 week low.

52 Week High

Mar
13
Tuesday

The 52 Week High stock price is $178.25 set on Tue, Mar 13, 2018 which is 39 days ago.

The current price per share is -11.28% below the 52 week high.

All Time High

Mar
13
Tuesday

The All Time High stock price is $178.25 set on Tue, Mar 13, 2018 which is 39 days ago.

The current price per share is -11.28% below the all time high.

Vertex Stock Charts

The 5 year and 1 year stock charts are below.

5 Year Stock Chart

The Vertex 5 year stock chart shows the historical prices over the previous 60 months.

Vertex 5 year stock chart

1 Year Stock Chart

The Vertex 1 year stock chart shows the historical prices over the previous 12 months.

Vertex 1 year stock chart

50 Day Moving Average

The 50 Day Moving Average is at $163.76 which is 3.43% above the stock price of $158.15.

200 Day Moving Average

The 200 Day Moving Average is at 154.56 which is -2.32% above the stock price of $158.15.

VRTX Company Profile

Vertex Pharmaceuticals Inc LogoVertex Pharmaceuticals Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $41.61 Billion.

http://www.vpharm.comVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

For more information and analysis about Vertex Pharmaceuticals Inc, visit their web site at http://www.vpharm.com. For a real time price lookup on this ticker, VRTX, visit Google Finance and Bloomberg.

Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .

VRTX Earnings

 Below is the EPS, P/E Ratio and Earnings Date.

Earnings Per Share

The EPS is $1.04.

Price To Earnings Ratio

The P/E Ratio is 157.60%.

Earnings Dates

Stocks can make big percentage moves on the earnings announcement.

Companies announce earnings either before the market open or after the close.

Jan
31
Wednesday

The Earnings Release Date for Vertex Pharmaceuticals Inc was Wed, Jan 31, 2018.

Since this earnings release 80 days ago, the stock price is down by -5.04%.

Apr
26
Thursday

The next Earnings Release Date is on Thu, Apr 26, 2018, which is in 5 days.

2018-04-26 06:00:002018-04-26 13:00:00America/New_YorkVertex Pharmaceuticals Inc (VRTX) EarningsVisit http://www.symbolsurfing.com/VRTX for more information.United StatesSymbol Surfinginfo@symbolsurfing.com

Vertex Dividend

VRTX currently does not pay a dividend.

You may like this list of best dividend stocks of 2018.